Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡

Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST

(2017) P. Reichardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of hand-foot syndrome (HFS) as a potential biomarker of sunitinib (SU) efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST).

(2017) I. Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure

(2012) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24

(2010) R. Goodwin et al.   ANNALS OF ONCOLOGY

Sunitinib for metastatic renal cell carcinoma

(2010) Deborah Mukherji et al.   Future Oncology

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

(2010) Mariëtte H.W. Kappers et al.   HYPERTENSION

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

(2010) Suzanne E. Dahlberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Vascular endothelial growth factor pathway

(2010) Michael L. Maitland et al.   Pharmacogenetics and Genomics

Hypertension as a surrogate marker for the activity of anti-VEGF agents

(2009) O. Mir et al.   ANNALS OF ONCOLOGY

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis

(2009) G. Di Lorenzo et al.   ANNALS OF ONCOLOGY

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

(2009) Brett E. Houk et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Rapid Development of Hypertension by Sorafenib: Toxicity or Target?

(2009) B. D. Humphreys et al.   CLINICAL CANCER RESEARCH

Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure

(2009) S. E. DePrimo et al.   CLINICAL CANCER RESEARCH

Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib Failure

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

(2009) S. George et al.   EUROPEAN JOURNAL OF CANCER

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

(2008) M. Scartozzi et al.   ANNALS OF ONCOLOGY

Molecular Pathobiology of Gastrointestinal Stromal Sarcomas

(2008) Christopher L. Corless et al.   Annual Review of Pathology-Mechanisms of Disease

Hypertension and proteinuria: a class-effect of antiangiogenic therapies

(2008) Vincent Launay-Vacher et al.   ANTI-CANCER DRUGS

Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor

(2008) N. Steeghs et al.   CLINICAL CANCER RESEARCH

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY